Compare First Solar, Inc. (FSLR) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs ResMed Inc. — how do they compare? First Solar, Inc. trades at $177.86 (market cap $19.22B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and ResMed Inc. for 51 Days on average.
| FSLR | RMD | |
|---|---|---|
Market Cap | $19.22B | $31.89B |
Volume | 2,067,793 | 618,314 |
Sector | Energy | Health |
52-Week High | $318.30 | $277.88 |
52-Week Low | $172.11 | $182.82 |
Typical Hold Time | 76 Days | 51 Days |
Enterprise Value | $17.69B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $177.82, down 1.28% on the day, amid a bearish technical signal and recent sector-wide pressures. The stock shows strong fundamentals with a P/E of 11.03, net income margin of 32.47%, and robust cash flow from operations of $2.06B in 2025. Recent news includes a patent infringement lawsuit filed on October 1, 2026, which briefly lifted the stock, while high put option volume on October 3, 2026, indicates investor caution.
FSLR presents a mixed outlook: solid profitability and analyst consensus support a 'Moderate Buy' with a $267.59 price target, but technical weakness and solar sector headwinds from high borrowing costs pose near-term risks. The stock's 44.9% decline from its all-time high highlights volatility, yet earnings beats in Q1 and Q2 2026 underscore operational strength.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
